With the most stocked clinical pipeline among its RNAi peers, Alnylam Pharmaceuticals Inc. has made the leap from platform to products, building on an IP position that has enabled revenue-generating deals that footed the bill...

Marina Biotech Inc. (NASDAQ:MRNA) proposed late Friday to raise $15 million through the sale of units in a follow-on. Further details were not disclosed. Marina (formerly MDRNA Inc. ) was up $0.01 to $0.69 on Monday....

Cypress acquired Marina's patent rights and technology related to an intranasal formulation of carbetocin. Cypress expects to start Phase II testing in 1Q11 for the long-acting analog of oxytocin to treat autism. Marina will receive...

Marina (formerly MDRNA Inc. ) disclosed in its 2Q10 earnings that it completed its previously announced acquisition of RNAi company Cequent in a stock deal. Cequent received 9.9 million Marina Biotech shares, valued at $31.6 million...

Marina (formerly MDRNA Inc. ) and the university extended by two years to June 2012 a 2008 deal to screen Marina's Trp Cage phage display library for peptides that Marina will use to improve and increase...

MDRNA Inc. implemented a 1-for-4 reverse stock split, changed its name to Marina Biotech Inc. and began trading under the symbol "MRNAD." Following the split, the company will have 12.2 million shares outstanding. Marina Biotech...

Marina (formerly MDRNA Inc. ) acquired novosom's Smarticles liposomal-based delivery technology for 1.4 million shares of Marina stock, valued at $3.8 million based on Marina's close of $2.67 on July 27, the day before the deal...

The companies added exclusive rights to develop and commercialize diagnostics using RiboTask's unlocked nucleobase analog (UNA) technology to a 2009 deal granting MDRNA rights to use the technology for human therapeutics. MDRNA said the expanded...

In mice, systemic delivery of 80 µg/kg UsiRNA targeting Factor VII in the liver resulted in 50% inhibition of Factor VII protein activity. Data were presented at the BIO International Conference in Chicago. The compound...

In a mouse model of orthotopic bladder cancer, intravesical delivery of UsiRNAs targeting fibroblast growth factor-3 (FGF-3; INT2 ) and survivin in a single formulation reduced both tumor bioluminescence and survivin mRNA expression by about 30%...